Sedation with propofol during ERCP: is the combination with esketamine more effective and safer than with alfentanil? Study protocol for a randomized controlled trial

• Published in: Current controlled trials in cardiovascular medicine 2017-10, Vol.18 (1), p.472-472, Article 472
• Main Authors: Eberl, Susanne, Koers, Lena, van Hooft, Jeanin E, de Jong, Edwin, Schneider, Thomas, Hollmann, Markus W, Preckel, Benedikt
• Format: Article
• Language: English
• Subjects: Alfentanil; Alfentanil - administration & dosage; Alfentanil - adverse effects; Anesthesia; Attitude of Health Personnel; Cholangiopancreatography, Endoscopic Retrograde; Clinical Protocols; Conscious Sedation - adverse effects; Conscious Sedation - methods; Drug Combinations; Drug dosages; Endoscopic retrograde cholangiopancreatography; Endoscopy; ERCP; Esketamine; Gastroenterology; Hepatology; Hospitals; Humans; Hypnotics and Sedatives - administration & dosage; Hypnotics and Sedatives - adverse effects; Informed consent; Intervention; Ketamine; Ketamine - administration & dosage; Ketamine - adverse effects; Methods; Netherlands; Patient Satisfaction; Plasma; Procedural sedation; Propofol; Propofol - administration & dosage; Propofol - adverse effects; Prospective Studies; Research Design; Study Protocol; Surveys and Questionnaires; Testing; Treatment Outcome
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-017-2197-8

Endoscopic retrograde cholangiopancreatography (ERCP) is a gastrointestinal procedure that requires a relatively motionless patient during the intervention. Deep sedation by intravenous propofol combined with an opioid has recently become the preferred sedation technique. However, when high doses of propofol are used, side effects, namely respiratory depression, may occur. Esketamine has hypnotic, analgesic, and sympathomimetic effects. Our assumption is that a combination of propofol with esketamine reduces the dosage of individual drugs, thereby minimizing sedation side effects while keeping the same satisfaction level of patients and endoscopists. The study will be performed as a randomized controlled multicenter trial. Patients undergoing ERCP, ≥ 18 years old, with American Society of Anesthesiologists (ASA) classification I-III will be randomized after written informed consent to group K (propofol/esketamine) or to group A (propofol/alfentanil). The primary outcome, reflecting effectiveness of sedation, is the total dose of propofol. Secondary outcome parameters are patients' and endoscopists' satisfaction with the procedure and the number of sedation-related pulmonary and cardiovascular events. Data on sedation-related events are collected by recording of oxygen saturation (SpO ), respiratory rate (RR), end-tidal CO (etCO ), heart rate (HR), arrhythmias (electrocardiogram (ECG)), and non-invasive blood pressure (NIBP) measurements. Satisfaction parameters are collected by means of questionnaires before and after the procedure and on the following day. Esketamine is known for its effective anesthetic and analgesic effects maintaining spontaneous breathing and airway reflexes. Due to an increase in sympathetic tone, hypotension and cardiac depression is less common. Unfortunately esketamine is also known for its psychotomimetic effects. We aim to demonstrate that the combination of esketamine with propofol for sedation in patients subjected to ERCP interventions is nevertheless superior to a combination of propofol with an opioid. Nederland's Trial Register, NTR5486 . Registered on 17 September 2015.